Travis Steed
Stock Analyst at Barclays
(2.74)
# 2,027
Out of 4,920 analysts
86
Total ratings
43.48%
Success rate
6.25%
Average return
Main Sectors:
Stocks Rated by Travis Steed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BDX Becton, Dickinson and Company | Maintains: Overweight | $279 → $261 | $176.89 | +47.55% | 9 | Apr 7, 2025 | |
| PEN Penumbra | Initiates: Buy | $320 | $240.10 | +33.28% | 1 | Mar 14, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $133 → $150 | $130.69 | +14.78% | 5 | Mar 10, 2025 | |
| SOLV Solventum | Maintains: Neutral | $80 → $85 | $72.43 | +17.35% | 3 | Feb 26, 2025 | |
| EW Edwards Lifesciences | Upgrades: Buy | $82 → $90 | $79.24 | +13.58% | 4 | Dec 16, 2024 | |
| CBLL CeriBell | Initiates: Buy | $32 | $15.08 | +112.20% | 1 | Nov 5, 2024 | |
| BAX Baxter International | Maintains: Neutral | $42 → $45 | $22.84 | +97.02% | 5 | Mar 5, 2024 | |
| OM Outset Medical | Downgrades: Underperform | $480 → $45 | $14.10 | +219.15% | 1 | Oct 13, 2023 | |
| SYK Stryker | Upgrades: Buy | $315 | $380.86 | -17.29% | 5 | Sep 5, 2023 | |
| PODD Insulet | Maintains: Buy | $365 → $295 | $281.00 | +4.98% | 3 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $13.72 | +16.62% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $33 | $15.15 | +117.82% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 → $160 | $92.05 | +73.82% | 11 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $315 | $477.00 | -33.96% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $8 | $1.64 | +387.80% | 1 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $25 | $9.91 | +152.40% | 1 | Jun 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $85 | $14.13 | +501.56% | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $75.46 | +65.65% | 7 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $145 | $89.67 | +61.70% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $51 | $104.83 | -51.35% | 9 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $175 | $53.50 | +227.10% | 4 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $59 → $54 | $12.72 | +324.70% | 2 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $72.63 | -69.71% | 1 | Jul 17, 2017 |
Becton, Dickinson and Company
Apr 7, 2025
Maintains: Overweight
Price Target: $279 → $261
Current: $176.89
Upside: +47.55%
Penumbra
Mar 14, 2025
Initiates: Buy
Price Target: $320
Current: $240.10
Upside: +33.28%
Abbott Laboratories
Mar 10, 2025
Maintains: Buy
Price Target: $133 → $150
Current: $130.69
Upside: +14.78%
Solventum
Feb 26, 2025
Maintains: Neutral
Price Target: $80 → $85
Current: $72.43
Upside: +17.35%
Edwards Lifesciences
Dec 16, 2024
Upgrades: Buy
Price Target: $82 → $90
Current: $79.24
Upside: +13.58%
CeriBell
Nov 5, 2024
Initiates: Buy
Price Target: $32
Current: $15.08
Upside: +112.20%
Baxter International
Mar 5, 2024
Maintains: Neutral
Price Target: $42 → $45
Current: $22.84
Upside: +97.02%
Outset Medical
Oct 13, 2023
Downgrades: Underperform
Price Target: $480 → $45
Current: $14.10
Upside: +219.15%
Stryker
Sep 5, 2023
Upgrades: Buy
Price Target: $315
Current: $380.86
Upside: -17.29%
Insulet
Aug 24, 2023
Maintains: Buy
Price Target: $365 → $295
Current: $281.00
Upside: +4.98%
Aug 22, 2023
Reiterates: Overweight
Price Target: $16
Current: $13.72
Upside: +16.62%
May 5, 2023
Downgrades: Underperform
Price Target: $45 → $33
Current: $15.15
Upside: +117.82%
May 3, 2023
Upgrades: Neutral
Price Target: $120 → $160
Current: $92.05
Upside: +73.82%
Apr 19, 2023
Maintains: Buy
Price Target: $300 → $315
Current: $477.00
Upside: -33.96%
Jan 3, 2023
Downgrades: Underperform
Price Target: $8
Current: $1.64
Upside: +387.80%
Jun 21, 2022
Initiates: Underperform
Price Target: $25
Current: $9.91
Upside: +152.40%
Oct 13, 2021
Maintains: Overweight
Price Target: $120 → $85
Current: $14.13
Upside: +501.56%
May 25, 2021
Initiates: Overweight
Price Target: $125
Current: $75.46
Upside: +65.65%
May 25, 2021
Initiates: Equal-Weight
Price Target: $145
Current: $89.67
Upside: +61.70%
May 25, 2021
Initiates: Overweight
Price Target: $51
Current: $104.83
Upside: -51.35%
May 25, 2021
Initiates: Overweight
Price Target: $175
Current: $53.50
Upside: +227.10%
Nov 1, 2018
Maintains: Neutral
Price Target: $59 → $54
Current: $12.72
Upside: +324.70%
Jul 17, 2017
Initiates: Overweight
Price Target: $22
Current: $72.63
Upside: -69.71%